Vizamyl
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer’s disease (AD), aid treatment…
Medicare’s decision to restrict coverage of florbetapir, a diagnostic agent for Alzheimer’s disease, exemplifies an inconsistent…
In Alzheimer’s disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary…
The application of microfluidics to the synthesis of Positron Emission Tomography (PET) tracers has been explored for more than a…
Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer’s disease…
Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer's disease…
2013年10月25日，美国食品药品监督管理局（FDA）批准由GE Healthcare Ltd的分公司Medi—Physics生产的放射性诊断药物[18F]flutemetamol注射液（Vizamyl）在美国上市。
Physicians in the US who want to see how much amyloid-beta protein has accumulated in the brains of their patients with Alzheimer…
There has been tremendous excitement regarding biomarkers that provide in vivo information on neurodegenerative diseases. Until…